NCT04631666View on ClinicalTrials.gov

SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

August 11, 2021

Study Completion Date

August 11, 2021

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

DZIF-10c

SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion

OTHER

Placebo

Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo

Trial Locations (1)

50937

University Hospital Cologne, Cologne

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

ZKS Köln

OTHER

collaborator

Boehringer Ingelheim

INDUSTRY

lead

University of Cologne

OTHER

NCT04631666 - SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion | Biotech Hunter | Biotech Hunter